Skip to main content

Table 3 Crude and adjusted mean Cito-test scores for different methylphenidate treatment characteristics

From: Methylphenidate use and school performance among primary school children: a descriptive study

1. MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
 Current users 532.80 ± 9.44 532.58 ± .48 377 <0.001***
 Never users 534.71 ± 9.47 534.72 ± .11 7295
2. Past versus current users School performance
Crude M ± SD Adjusteda M ± SE n p value
 Current users (n = 377) 532.80 ± 9.44 532.58 ± .48 377 .470
 Past users (n = 64) 531.52 ± 10.70 531.67 ± 1.15 64
3. Dosage of MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
  ≤ 0.999 NDDD/Day 533.17 ± 9.60 533.16 ± .66 202 .498
  > 0.999 NDDD/Day 532.44 ± 9.28 532.45 ± .81 132
4. Start of MPH treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
 Late start ≤12 months 536.37 ± 8.62 536.94 ± 1.51 38 .004**
 Early start >12 months 532.40 ± 9.46 532.33 ± .50 339
5. Concurrent treatment School performance
Crude M ± SD Adjusteda M ± SE n p value
 Only MPH 532.72 ± 9.45 532.70 ± .497 347 .937
 MPH + AP 532.47 ± 9.71 532.87 ± 2.13 19
 Only asthma medication 537.10 ± 8.52 536.90 ± .865 100 .845
 MPH + asthma medication 535.64 ± 8.94 537.49 ± 2.86 11
  1. Abbreviations: M, mean; SD, standard deviation; SE, standard error; n; sample size*Significant at the .05 level
  2. **Significant at the 0.01 level
  3. ***Significant at the 0.001 level
  4. aAdjusted for sex, ethnicity, parent household, and household income